Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA.
Identifieur interne : 000B29 ( Main/Exploration ); précédent : 000B28; suivant : 000B30Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA.
Auteurs : RBID : pubmed:22172396English descriptors
- KwdEn :
- Acetates (chemistry), Animals, Antibodies, Monoclonal (chemistry), Antibodies, Monoclonal (immunology), Antibodies, Monoclonal (pharmacokinetics), Binding Sites, Cell Line, Tumor, Chelating Agents (chemistry), Heterocyclic Compounds, 1-Ring (chemistry), Humans, Indium Radioisotopes (chemistry), Isotope Labeling (methods), Male, Maleimides (chemistry), Mice, Receptor, erbB-2 (immunology), Recombinant Fusion Proteins (chemistry), Recombinant Fusion Proteins (immunology), Recombinant Fusion Proteins (pharmacokinetics), Substrate Specificity, Sulfhydryl Compounds (chemistry).
- MESH :
- chemical , chemistry : Acetates, Antibodies, Monoclonal, Chelating Agents, Heterocyclic Compounds, 1-Ring, Indium Radioisotopes, Maleimides, Recombinant Fusion Proteins, Sulfhydryl Compounds.
- chemical , immunology : Antibodies, Monoclonal, Receptor, erbB-2, Recombinant Fusion Proteins.
- chemical , pharmacokinetics : Antibodies, Monoclonal, Recombinant Fusion Proteins.
- methods : Isotope Labeling.
- Animals, Binding Sites, Cell Line, Tumor, Humans, Male, Mice, Substrate Specificity.
Abstract
Affibody molecules have demonstrated potential for radionuclide molecular imaging. The aim of this study was to synthesize and evaluate a maleimido derivative of the 1,4,7-triazacyclononane-1-glutaric acid-4,7-diacetic acid (NODAGA) for site-specific labeling of anti-HER2 Affibody molecule.
DOI: 10.1016/j.nucmedbio.2011.10.013
PubMed: 22172396
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA.</title><author><name sortKey="Altai, Mohamed" uniqKey="Altai M">Mohamed Altai</name><affiliation wicri:level="1"><nlm:affiliation>Unit of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Unit of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala</wicri:regionArea></affiliation></author><author><name sortKey="Perols, Anna" uniqKey="Perols A">Anna Perols</name></author><author><name sortKey="Karlstr M, Amelie Eriksson" uniqKey="Karlstr M A">Amelie Eriksson Karlström</name></author><author><name sortKey="Sandstr M, Mattias" uniqKey="Sandstr M M">Mattias Sandström</name></author><author><name sortKey="Boschetti, Frederic" uniqKey="Boschetti F">Frederic Boschetti</name></author><author><name sortKey="Orlova, Anna" uniqKey="Orlova A">Anna Orlova</name></author><author><name sortKey="Tolmachev, Vladimir" uniqKey="Tolmachev V">Vladimir Tolmachev</name></author></titleStmt><publicationStmt><date when="2012">2012</date><idno type="doi">10.1016/j.nucmedbio.2011.10.013</idno><idno type="RBID">pubmed:22172396</idno><idno type="pmid">22172396</idno><idno type="wicri:Area/Main/Corpus">001005</idno><idno type="wicri:Area/Main/Curation">001005</idno><idno type="wicri:Area/Main/Exploration">000B29</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetates (chemistry)</term><term>Animals</term><term>Antibodies, Monoclonal (chemistry)</term><term>Antibodies, Monoclonal (immunology)</term><term>Antibodies, Monoclonal (pharmacokinetics)</term><term>Binding Sites</term><term>Cell Line, Tumor</term><term>Chelating Agents (chemistry)</term><term>Heterocyclic Compounds, 1-Ring (chemistry)</term><term>Humans</term><term>Indium Radioisotopes (chemistry)</term><term>Isotope Labeling (methods)</term><term>Male</term><term>Maleimides (chemistry)</term><term>Mice</term><term>Receptor, erbB-2 (immunology)</term><term>Recombinant Fusion Proteins (chemistry)</term><term>Recombinant Fusion Proteins (immunology)</term><term>Recombinant Fusion Proteins (pharmacokinetics)</term><term>Substrate Specificity</term><term>Sulfhydryl Compounds (chemistry)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Acetates</term><term>Antibodies, Monoclonal</term><term>Chelating Agents</term><term>Heterocyclic Compounds, 1-Ring</term><term>Indium Radioisotopes</term><term>Maleimides</term><term>Recombinant Fusion Proteins</term><term>Sulfhydryl Compounds</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Receptor, erbB-2</term><term>Recombinant Fusion Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Recombinant Fusion Proteins</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Isotope Labeling</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Binding Sites</term><term>Cell Line, Tumor</term><term>Humans</term><term>Male</term><term>Mice</term><term>Substrate Specificity</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Affibody molecules have demonstrated potential for radionuclide molecular imaging. The aim of this study was to synthesize and evaluate a maleimido derivative of the 1,4,7-triazacyclononane-1-glutaric acid-4,7-diacetic acid (NODAGA) for site-specific labeling of anti-HER2 Affibody molecule.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">22172396</PMID><DateCreated><Year>2012</Year><Month>04</Month><Day>30</Day></DateCreated><DateCompleted><Year>2012</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2012</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9614</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>4</Issue><PubDate><Year>2012</Year><Month>May</Month></PubDate></JournalIssue><Title>Nuclear medicine and biology</Title><ISOAbbreviation>Nucl. Med. Biol.</ISOAbbreviation></Journal><ArticleTitle>Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA.</ArticleTitle><Pagination><MedlinePgn>518-29</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nucmedbio.2011.10.013</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Affibody molecules have demonstrated potential for radionuclide molecular imaging. The aim of this study was to synthesize and evaluate a maleimido derivative of the 1,4,7-triazacyclononane-1-glutaric acid-4,7-diacetic acid (NODAGA) for site-specific labeling of anti-HER2 Affibody molecule.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The maleimidoethylmonoamide NODAGA (MMA-NODAGA) was synthesized and conjugated to Z(HER2:2395) Affibody molecule having a C-terminal cysteine. Labeling efficiency, binding specificity to and cell internalization by HER2-expressing cells of [(111)In-MMA-NODAGA-Cys(61)]-Z(HER2:2395) were studied. Biodistribution of [(111)In-MMA-NODAGA-Cys(61)]-Z(HER2:2395) and [(111)In-MMA-DOTA-Cys(61)]-Z(HER2:2395) was compared in mice.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The affinity of [MMA-NODAGA-Cys(61)]-Z(HER2:2395) binding to HER2 was 67 pM. The (111)In-labeling yield was 99.6%±0.5% after 30 min at 60°C. [(111)In-MMA-NODAGA-Cys(61)]-Z(HER2:2395) bound specifically to HER2-expressing cells in vitro and in vivo. Tumor uptake of [(111)In-MMA-NODAGA-Cys(61)]-Z(HER2:2395) in mice bearing DU-145 xenografts (4.7%±0.8% ID/g) was lower than uptake of [(111)In-MMA-DOTA-Cys(61)]-Z(HER2:2395) (7.5%±1.6% ID/g). However, tumor-to-organ ratios were higher for [(111)In-MMA-NODAGA-Cys(61)]-Z(HER2:2395) due to higher clearance rate from normal tissues.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">MMA-NODAGA is a promising chelator for site-specific labeling of targeting proteins containing unpaired cysteine. Appreciable influence of chelators on targeting properties of Affibody molecules was demonstrated.</AbstractText><CopyrightInformation>Copyright © 2012 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Altai</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><Affiliation>Unit of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.</Affiliation></Author><Author ValidYN="Y"><LastName>Perols</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Karlström</LastName><ForeName>Amelie Eriksson</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Sandström</LastName><ForeName>Mattias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Boschetti</LastName><ForeName>Frederic</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Orlova</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Tolmachev</LastName><ForeName>Vladimir</ForeName><Initials>V</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Journal Article</PublicationType><PublicationType>Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>12</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nucl Med Biol</MedlineTA><NlmUniqueID>9304420</NlmUniqueID><ISSNLinking>0969-8051</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>1-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-triazacyclononane</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Acetates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Chelating Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Heterocyclic Compounds, 1-Ring</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Maleimides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Sulfhydryl Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>541-59-3</RegistryNumber><NameOfSubstance>maleimide</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance>Receptor, erbB-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Acetates</DescriptorName><QualifierName MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName MajorTopicYN="Y">chemistry</QualifierName><QualifierName MajorTopicYN="N">immunology</QualifierName><QualifierName MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Chelating Agents</DescriptorName><QualifierName MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Heterocyclic Compounds, 1-Ring</DescriptorName><QualifierName MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Isotope Labeling</DescriptorName><QualifierName MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Maleimides</DescriptorName><QualifierName MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Receptor, erbB-2</DescriptorName><QualifierName MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName MajorTopicYN="Y">chemistry</QualifierName><QualifierName MajorTopicYN="N">immunology</QualifierName><QualifierName MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Substrate Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Sulfhydryl Compounds</DescriptorName><QualifierName MajorTopicYN="N">chemistry</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2011</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">S0969-8051(11)00246-0</ArticleId><ArticleId IdType="doi">10.1016/j.nucmedbio.2011.10.013</ArticleId><ArticleId IdType="pubmed">22172396</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B29 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000B29 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:22172396
|texte= Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22172396" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |